Clinical trials: Urinary Symptoms
Urinary Bladder, Overactive
The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
This is an open-label, randomized, two-way crossover study to evaluate the steady-state effect of fesoterodine (8 mg QD) on the pharmacodynamics and pharmacokinetics of a single supratherapeutic dose of warfarin (25 mg) in…
- Trial name
- NCT00914667
- Testing
- warfarin, Warfarin plus Fesoterodine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nocturia
Daytime Impact Sleep Study
This trial will investigate the relationship of sleep, daytime performance and nocturia in patients treated with Desmopressin or placebo.
- Trial name
- DAISS (NCT01779466)
- Testing
- Desmopressin
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Ferring Pharmaceuticals
Urinary Tract Infections, Infectious Diarrhea
Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
The purpose of this study is to assess the feasibility of TrueLoo™, an Internet-connected smart toilet seat, in accurately monitoring and logging bowel movements and urinations of residents in senior living facilities across…
- Conditions
- Urinary Tract Infections, Infectious Diarrhea, Clostridium Difficile Infection, Gastrointestinal Disease
- Trial name
- NCT05008640
- Testing
- TrueLoo™
- Where
- 6 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Toi Labs, Inc.
Urinary Incontinence, Stress
A 3 Years Naturalistic Cohort Survey of Altis Single Incision Sling System For Female Stress Urinary Incontinence
The purpose of this study is to monitor the use of Altis Single Incision Sling (SIS) in a real world population and collect medical data on effectiveness and to monitor safety of Altis SIS at 12 and 36 months post device…
- Trial name
- NCT04115605
- Testing
- Altis Single Incision Sling
- Where
- 33 sites in Belgium, France and 3 more
- Volunteers
- 598 people
- Sponsor
- Coloplast A/S
Urinary Bladder, Overactive
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
GSK1358820 is a botulinum neurotoxin A complex that has been approved for the treatment of overactive bladder (OAB) in several countries, however, it has not been approved for OAB treatment in Japan.
- Trial name
- NCT02820844
- Testing
- GSK1358820, Antibiotic therapy, Bladder diary
- Where
- 48 sites in Japan
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Nocturia
A Study of Minirin Melt in Patients With Nocturia
This is a confirmation of safety profile for Minirin Melt in clinical practice.
- Trial name
- NCT01222598
- Where
- 37 sites in Czechia
- Volunteers
- 588 people
- Sponsor
- Ferring Pharmaceuticals
Urinary Bladder, Overactive
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.
- Trial name
- NCT01157377
- Testing
- AGN-214868
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 160 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT01107392
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer
Urinary Incontinence
Athena Pelvic Muscle Trainer - DUETS Trial
The purpose of this study is to determine if the Athena Pelvic Muscle Trainer device effectively treats stress, urge or mixed incontinence in women by strengthening the pelvic floor muscles by collecting data from the patient on…
- Trial name
- DUETS (NCT01073878)
- Testing
- Athena Pelvic Muscle Trainer
- Where
- 97 sites in United States, Virgin Islands
- Volunteers
- 462 people
- Sponsor
- Athena Feminine Technologies, Inc.
Overactive Bladder
Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder
To determine the efficacy and safety of Botulax® in treatment of Overactive Bladder
- Trial name
- NCT04186442
- Testing
- Botulinum toxin type A injection, Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Hugel
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
A post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the…
- Trial name
- NCT04658056
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- PROCEPT BioRobotics
Urinary Urge Incontinence
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
- Trial name
- NCT06217328
- Testing
- Revi System Treatment, Revi System - Delayed Activation
- Where
- 19 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- BlueWind Medical
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Refractory Overactive Bladder
Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)
Evaluate the long-term clinical effectiveness and safety of the PINS Sacral Neuromodulation to patients with refractory Overactive Bladder.
- Trial name
- NCT02619721
- Testing
- PINS SNS
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Urinary Incontinence
Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence
The purpose of this study is to compare the side-effect profile and efficacy of sustained release, OROS® and TTS, dosage forms of oxybutynin with immediate release (IR) oral oxybutynin and with placebo.
- Trial name
- NCT00304499
- Testing
- Oxybutynin
- Volunteers
- 176 people
- Sponsor
- Alza Corporation, DE, USA
Urinary Incontinence Stress
Open Label Phase III Duloxetine Study for Stress Urinary Incontinence
The purpose of this study is to monitor the long term safety of duloxetine in the treatment of stress urinary incontinence.
- Trial name
- NCT00191204
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 363 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
A Therapeutic Exploratory Clinical Study to evaluate the efficacy and safety of DA-8010 in Patients with Overactive Bladder and to determine the optimal dose of DA-8010
- Trial name
- NCT03566134
- Testing
- DA-8010 2.5mg, DA-8010 5mg, Solifenacin 5mg
- Where
- South Korea
- Volunteers
- 306 people
- Sponsor
- Dong-A ST Co., Ltd.
Bladder Function
A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)
This is an observational, pilot, non-treatment study to evaluate and develop clinical variables for distinguishing female OAB subjects that have detrusor overactivity positive (DO+) nocturia from female OAB subjects that have…
- Trial name
- NCT01099345
- Testing
- cystometry (CMG), polysomnography (PSG)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Inc
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH
The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH.
- Trial name
- NCT04627701
- Testing
- Omega
- Where
- 4 sites in Israel, New Zealand
- Volunteers
- 26 people
- Sponsor
- ProArc Medical